Numinus Wellness Inc. Stock Price, News & Analysis

Numinus Wellness (OTCQB: NUMIF) announced an auditor change on October 10, 2025: Davidson & Company LLP resigned and MNP LLP has been engaged as the new independent auditor.

The company stated the audit for the year ended August 31, 2025 is on track to be completed by MNP by the end of November 2025. Prior reports from Davidson for fiscal years 2020–2024 were unmodified and contained no reportable events under National Instrument 51-102. The Audit Committee and Board approved the change. The company remains in the process of lifting a cease trade order and relisting on another exchange.

Numinus Wellness Inc. (OTCQB: NUMIF), a mental health care company specializing in psychedelic-assisted therapies, reported its Q3 2025 financial results. The company achieved significant growth with revenue increasing 81.6% to $1.8 million compared to Q3 2024. Cedar Clinical Research operations saw a 95.8% revenue increase to $1.6 million, while Practitioner Training revenue grew by 12.3%.

The company demonstrated improved operational efficiency with gross margin reaching 48.2% compared to -4.6% in Q3 2024, and operating expenses decreased to $1.5 million from $3.8 million. The company ended Q3 with a cash balance of $822,835 and is working to revoke an ongoing cease trade order to relist on another exchange.

Numinus is strategically repositioning itself from a direct care provider to a comprehensive infrastructure provider for psychedelic medicine delivery, leveraging its experience of serving over 50,000 individuals across 200,000 appointments.

Numinus Wellness (OTCQB:NUMIF), a mental health care company specializing in psychedelic-assisted therapies, reported its Q2 2025 financial results. The company achieved total revenue of C$1.51 million, representing an 83.8% increase from Q2 2024. Despite revenue growth, gross profit margin declined to 33.4% from 55.6% year-over-year.

The company reported a comprehensive loss of C$7.71 million, wider than the previous year's loss of C$5.96 million. Operating expenses increased by 86.31% to C$9.89 million. As of February 28, 2025, Numinus maintained cash and cash equivalents of C$705,631.

Numinus Wellness (OTCQB: NUMIF), a mental health care company specializing in psychedelic-assisted therapies, reported its Q1 2025 financial results. The company achieved significant revenue growth of 68.3%, reaching $2.01 million compared to $1.20 million in Q1 2024.

The company demonstrated improved operational efficiency with a gross profit margin increase to 49.3% from 38.6% year-over-year. Operating expenses decreased substantially by 51.1% to $2.07 million. The net loss narrowed to $1.29 million from $4.35 million in the prior year. As of November 30, 2024, Numinus maintained a cash position of $2.0 million.

Numinus Wellness Inc. (OTCQB:NUMIF), a mental health care company specializing in psychedelic-assisted therapies, reported its Q4 2024 financial results. The company achieved revenue of $1.2 million, marking a 16.4% increase from Q3 2024, with a gross profit of $0.3 million.

Key developments include the sale of its wellness clinic network to Stella for US$3.53 million, leadership changes with Michael Tan appointed as CEO, and the approval of its Psychedelic-Assisted Therapy Training Program in Colorado. Cedar Clinical Research (CCR) managed 18 clinical trials and was selected as one of 15 U.S. research sites for Cybin's Phase 3 trial of CYB003 for Major Depressive Disorder.

The company ended Q4 with $2.0 million in cash and has successfully transitioned to a leaner operation, focusing on growth through its clinical research and practitioner training segments.

Numinus Wellness (TSX: NUMI, OTCQB: NUMIF) has achieved a significant milestone as its Psychedelic-Assisted Therapy Training Program received official approval from Colorado state under the Natural Medicine Health Act (Proposition 122). This certification enables the company to train licensed professionals in providing psilocybin services.

The comprehensive certification pathway includes coursework in psychedelic-assisted therapy fundamentals, psilocybin-specific training, trauma-informed care, and practical applications. Healthcare practitioners, including therapists, social workers, and medical professionals, can enroll through an online application process, complete required courses, undergo supervised practicum in Colorado, and pass a final certification exam.

In a corporate update, Numinus disclosed that it has submitted all required information for its year-end financial audit and is working with auditors to complete the process and lift the current cease trade order.

Numinus Wellness (TSX: NUMI, OTCQX: NUMIF) announced a transition in its Chief Financial Officer position. Kelvin Yang will take over as Interim CFO effective February 18, 2025, replacing Melony Valleau, who will conclude her interim tenure at the end of February. Yang brings regulatory and compliance experience and will oversee the company's financial operations as it pursues its strategic initiatives. The transition has been approved by the Board of Directors and aligns with ongoing corporate planning.

Numinus Wellness Inc. (TSX: NUMI, OTCQX: NUMIF) announced a strategic wind-down of several non-operating subsidiaries through bankruptcy proceedings to streamline its corporate structure and improve operational efficiency. The affected subsidiaries include Mindspace Services Inc., Neurology Centre of Toronto Inc., Numinus Bioscience Inc., Salvation Bioscience Inc., and Numinus Health Corp.

The company emphasized that these actions will not affect Numinus Wellness Inc.'s ability to continue operations, as it maintains focus on its core research and training businesses in mental health solutions and psychedelic-assisted therapies. Dodick Landau Inc. has been engaged to oversee the bankruptcy proceedings, and the company will ensure completion of all required CRA filings for the affected entities.

Numinus Wellness (TSX: NUMI, OTCQX: NUMIF) announced key leadership changes, with Michael Tan appointed as CEO, succeeding Payton Nyquvest who transitions to Executive Chair. Tan, who joined as COO in 2019 and became President in 2022, has overseen operations, M&A activities, and organizational realignments. In his new role, he will focus on strengthening clinical research and practitioner training programs while addressing emerging mental health care opportunities.

Nyquvest will remain actively involved in corporate strategy, investor relations, and strategic partnerships. The company also announced the resignation of Allen Morishita from its Board of Directors, who has served since Numinus' inception.